An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
The purpose of this study is to determine if ganetespib (STA-9090) is effective in the
 treatment of patients with HER2+ or triple negative breast cancer who have not received prior
 systemic treatment in the metastatic setting.
Inclusion Criteria:

 -  Pathologically confirmed diagnosis of invasive breast cancer.

 -  Stage IV disease.

 -  Documented HER2 and hormonal receptor status per protocol, ER/PR+ patients must be
 refractory to at least one prior hormonal treatment.

 -  ECOG Performance status 0-1.

 -  Measurable disease per RECIST (1.1).

 -  Adequate hematological function per protocol.

 -  Adequate hepatic function per protocol.

 -  Adequate renal function per protocol.

 -  Negative serum pregnancy test at study entry for patients of childbearing potential.

 -  Ability to understand and sign written consent and to comply with the study protocol.

 Exclusion Criteria:

 -  Presence of active or untreated CNS metastases as determined by MRI/CT scan performed
 during screening.

 -  Active malignancies other than MBC within the last 5 years except adequately treated
 in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin.

 -  Bone as the only site of metastatic disease from breast cancer.

 -  Prior radiotherapy to the only area of measurable disease. NOTE: Radiotherapy to a
 limited area other than the sole site of measurable disease is allowed, if received
 prior to initiation of ganetespib treatment. Patients must have completed treatment
 and recovered from all acute treatment-related toxicities prior to administration of
 first dose of ganetespib.

 -  Pregnancy or lactation.

 -  Known serious cardiac illness.

 -  Uncontrolled intercurrent illness per protocol.

 -  Other severe acute or chronic medical condition or abnormality that may increase the
 risk associated with study participation or study drug administration, or may
 interfere with the interpretation of study results, or that in the judgment of the
 investigator would make the patient inappropriate for entry into the study.